Page last updated: 2024-11-06

nicaraven

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nicaraven: an antivasospastic substance [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71234
CHEMBL ID1705525
SCHEMBL ID677580
MeSH IDM0125766

Synonyms (63)

Synonym
AC-19733
antevas
nicaraven
avs
ccris 7280
n,n'-(1-methyl-1,2-ethanediyl)bis-3-pyridinecarboxamide
3-pyridinecarboxamide, n,n'-(1-methyl-1,2-ethanediyl)bis-
1,2-bis(nicotinamido)propane
(+-)-n,n'-propylenebis(nicotinamide)
n,n'-propylenenicotinamide
nicaraven [inn]
(+-)-n,n'-propylenedinicotinamide
nicaravenum [inn-latin]
NCGC00160494-01
STK496402
n,n'-propane-1,2-diyldipyridine-3-carboxamide
n-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide
79455-30-4
AKOS001681527
unii-ud8pev6jbd
nicaravenum
ud8pev6jbd ,
dtxcid4026189
dtxsid6046189 ,
tox21_111854
cas-79455-30-4
S4265
BCP9000987
BCP0726000143
FT-0645369
CHEMBL1705525
MLS006010102
smr004701241
SCHEMBL677580
160888-15-3
nicaraven [jan]
nicaraven [mart.]
nicaraven [mi]
(+/-)-n,n'-propylenebis(nicotinamide)
AKOS016844293
KTXBOOWDLPUROC-UHFFFAOYSA-N
n,n'-(propane-1,2-diyl)dinicotinamide
AC-32631
457KF8A3QQ ,
409303-59-9
nicaraven, (-)-
nicaraven, (+)-
K13EV3J70Q
3-pyridinecarboxamide, n,n'-(1-methyl-1,2-ethanediyl)bis-, (-)-
3-pyridinecarboxamide, n,n'-(1-methyl-1,2-ethanediyl)bis-, (+)-
unii-457kf8a3qq
HMS3652P04
mfcd00411904
SW219515-1
CS-6342
HY-100592
BCP03758
n,n inverted exclamation marka-(1-methyl-1,2-ethanediyl)bis[3-pyridinecarboxamide]
DB06397
AS-15176
HMS3885L15
CCG-267306
n-{1-[(pyridin-3-yl)formamido]propan-2-yl}pyridine-3-carboxamide

Research Excerpts

Overview

Nicaraven is an agent that is especially beneficial in vasospasm or brain damage caused by subarachnoid hemorrhage.

ExcerptReferenceRelevance
"Nicaraven is an agent that is especially beneficial in vasospasm or brain damage caused by subarachnoid hemorrhage. "( Possible role of nicaraven in neuroprotective effect on hippocampal slice culture.
Manome, Y; Watanabe, M; Yoshinaga, H, 2003
)
2.1
"Nicaraven is a drug used for patients with a subarachnoid hemorrhage. "( Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death.
Akiyama, N; Manome, Y; Mori, M; Sekine, H; Watanabe, M,
)
1.81

Actions

ExcerptReferenceRelevance
"Nicaraven did not inhibit the activation of the Egr-1 promoter caused by H2O2 and the activation caused by ionizing radiation. "( Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death.
Akiyama, N; Manome, Y; Mori, M; Sekine, H; Watanabe, M,
)
1.81

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Prior exposure to FeSO4/H2O2 produced significant endothelial damage as reflected by the right-ward shift of the dose-response curve of bradykinin-induced endothelium-dependent relaxation."( Hydroxyl radical scavenging effect of nicaraven in myocardial and coronary endothelial preservation and reperfusion injury.
Alam, MS; Hashimoto, M; Ku, K; Masumura, S; Nakayama, K; Nosaka, S; Saitoh, Y; Tamura, K; Yamauchi, M, 1997
)
0.57
" We evaluated the effects of hydroxyl radical scavenger AVS [(+/-)-N,N'-propylenedinicotinamide; Nicaraven] after experimental SAH on rodent behavioral deficits (employing a battery of well-characterized assessment tasks over a 2-day observation period) and blood-brain barrier (BBB) permeability changes two days after SAH (quantifying the microvascular alterations according to the extravasation of protein-bound Evans Blue using a spectrophotofluorimetric technique) in dose-response and time-window experiments."( Effects of the radical scavenger AVS on behavioral and BBB changes after experimental subarachnoid hemorrhage.
Costa, G; d'Avella, D; Germanò, A; Imperatore, C; Tomasello, F, 2000
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.81840.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (9.52)18.7374
1990's15 (35.71)18.2507
2000's12 (28.57)29.6817
2010's5 (11.90)24.3611
2020's6 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.56 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.22%)5.53%
Reviews4 (8.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]